Creative Medical Technology Holdings, Inc. (CELZ)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 3K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 2K | 0.00 |
| Operating Income | -1.3M | -1.3M | -1.9M | -1.5M |
| Net Income | -1.2M | -1.2M | -1.9M | -1.4M |
| Diluted EPS | $-0.48 | $-0.48 | $nan | $-0.38 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 89K | 9K | 11K | 6K |
| Gross Profit | 60K | 5K | 7K | 4K |
| Operating Income | -10.2M | -5.6M | -5.7M | -6.1M |
| Net Income | -10.1M | -5.3M | -5.5M | -6.0M |
| Diluted EPS | $-9.28 | $-3.76 | $-3.71 | $-2.52 |